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Summary
Background Immunotherapy is a recognized treatment for allergic respiratory diseases.
Objective To study the usefulness of immunotherapy in combination with optimal pharmacological
therapy.
Methods Thirty-eight children (8–14 years) suffering from seasonal asthma7rhinoconjunctivitis
due to Parietaria poorly controlled by anti-allergic drugs treatment were selected. After randomi-
zation according to a double-blind placebo-controlled design they received active sublingual
immunotherapy (15 children) or placebo (15 children) for 13 months combined with inhaled
ﬂuticasone twice a day during the pollen season. Eight children were taken as control, whereas all
patients were instructed to take symptomatic drugs on need. Early and late skin response to the
allergen were assessed in all patients before and after treatment. Drug and symptom scores, as well as
visual analogue scores (VASs) and Parietaria pollen counts were assessed during the pollen season.
Results Groups were well balanced for age, gender, early and late skin response before treatment.
Four children dropped out, in one case in relationship with active sublingual immunotherapy (SLIT)
administration. Chest and nose symptoms, as well as drug scores and VASs were signiﬁcantly better
in both the active or placebo SLIT1ﬂuticasone (S1F) as compared to the control group (P between
o0.001 and 0.043). Eye symptoms were signiﬁcantly better in the active S1F group as compared to
control (P5 0.025). The VASs were signiﬁcantly better in the active S1F group as compared to the
placebo S1F group (P5 0.037). The early skin response decreased signiﬁcantly in the active S1F
group (Po0.001), whereas the late skin response changed signiﬁcantly in all groups, with an increase
in the placebo1ﬂuticasone group (P5 0.019) and in the control group (P5 0.037) and a decrease
(Po0.0001) in the active S1F group.
Conclusion The clinical efﬁcacy of S1F is equal to that of ﬂuticasone alone, but the addition of
SLIT has effects also on non-bronchial symptoms.
Keywords children, early skin response, ﬂuticasone, late skin response, Parietaria pollen, sublingual
immunotherapy, visual analog score
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Introduction
Injection allergen-speciﬁc immunotherapy (SCIT) for aller-
gens such as grass, Parietaria, Ambrosia, mites, and
hymenoptera venom has been recognized as effective on the
basis of the decrease of respiratory symptoms and rescue
drugs in treated patients in double-blind, placebo-controlled
studies. Moreover, SCIT is now deﬁned as an immunological
response modiﬁer, being able to positively interfere with the
natural history of allergy [1, 2].
The mechanism of action of SCIT has not yet been deﬁned
in detail, but a switch of T lymphocytes from Th2 to Th1
accompanied by a reduced production of IL-4, IL-5, and
IL-13 cytokines has been repeatedly reported [3–6].
Over the past 10 years, the interest for the non-injection
routes of administration of immunotherapy has been rapidly
increasing and a large number of clinical trials have been
published in the last few years (for a revision, see refs. (1, 2)).
Among the so-called ‘local routes’ of SIT, sublingual
immunotherapy (SLIT) has been deeply studied and investi-
gated from a clinical point of view and recognized as safe and
effective in adults as well as children [1, 2].
All of the trials so far performed were mainly aimed at
demonstrating the clinical efﬁcacy and the safety of SLIT.
However, these conclusions merely demonstrate efﬁcacy
compared to placebo.
For immunotherapy to retain a place in the treatment of
seasonal asthma as additional therapy in asthmatic children
already treated with inhaled steroids, we thought that a
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double-blind, placebo-controlled study in highly sensitive
patients to Parietaria pollen was needed.
We chose for our trial a biologically standardized prepara-
tion already documented for efﬁcacy and low incidence of
side-effects [7–10].
Materials and methods
Patients
Thirty-eight children (age range 8–14 years) were selected
according to the following criteria:
 history of seasonal asthma and rhinoconjunctivitis. The
diagnosis of asthma was established on the basis of at least
three doctor-diagnosed episodes separated by at least
1 week of wheezing/breath difﬁculty during the two pre-
vious Parietaria pollen seasons in a clinical setting where
asthma was likely and conditions other than allergy had
been excluded [11]
 poor symptom control in previous years despite anti-
allergic treatment including antihistamines, inhaled corti-
costeroids and nedocromil sodium for 3–4 months (i.e.
almost the full pollen season)
 positive skin prick test result (weal diameterX5mm) to
Parietaria pollen extract (Parietaria judaica – Soluprick
ALK, Horsholm, Denmark);
 Speciﬁc IgE to P. judaica levels in sera of at least class 2 was
determined by means of the RAST-EIA technique (Phar-
macia Diagnostics AB, Uppsala, Sweden).
Patients were excluded if they or their parents reported any of
the following situations:
 appreciable clinical history of sensitization to other
inhalant allergens (conﬁrmed by skin prick test and/or in
vitro IgE analysis). Two patients belonging to the active
group and one belonging to the placebo group were skin-
test positive to mites, but they were included because they
had no clinical symptoms of allergy due to mites and
showed a reactivity to methacholine42mg/mL in autumn.
 a history of previous immunotherapy;
 severe asthma (forced expiratory volume in 1 s (FEV1)
values below 70% of predicted values);
 a history of cardiovascular or other medical or immuno-
logical diseases.
Children showing at baseline a methacholine PC20 (concen-
tration of inhaled methacholine that caused a 20% decrease
in FEV1) below 2mg/mL were also excluded so as to include
only children with mild or no aspeciﬁc bronchial hyper-
reactivity outside the pollen season of Parietaria.
The EAACI Position Paper contraindications [12] were
followed in other cases.
Demographic and clinical data of patients are shown in
Table 1.
Study design
The study was performed with the approval of the University
of Messina Polyclinic Hospital Ethics Committee and the
children’s parents were required to sign an informed consent.
The recruitment of patient was completed during or
immediately after the 1999 peak pollen season of Parietaria.
Thirty out of 38 recruited children were randomized to active
SLIT (P. judaica) or placebo according to a double-blind
design started in September 1999.
Eight asthmatic children, not treated with active or placebo
SLIT, were taken as control group.
The randomization to the active (15 children), placebo (15
children), or control (8 children) group was obtained by
means of a computer-generated key-code. Both SLIT groups
(active and placebo) were prescribed and instructed to use
rescue drugs during the peak of the following pollen season of
Parietaria (i.e. from April to June 2000). They also inhaled
ﬂuticasone propionate (50mg per actuation) twice daily,
whereas the control group received only rescue drugs. All
patients were asked to use allowed rescue medications
regularly until improvement of symptoms.
The co-ordinator, who was blinded as to the group each
child was assigned to, was in charge of patient’s supervision
and adjustment of rescue medications according to symptoms.
He was also responsible for reporting any reaction and/or
side-effects certainly or possibly related to the treatment.
Immunotherapy protocol and pharmacological treatment
The administration of SLIT to children belonging to the
active or placebo group began in the ﬁrst 2 weeks of
September 1999 and was continued until October 2000. The
Table 1. Demographic data
SLIT1fluticasone Placebo1fluticasone Control group
No. of patients 15 15 8
Drop-outs 1 2 1
Sex (M/F) 7/8 6/9 5/3
Age (mean in years) 11 11 10
Age (range in years) 8–14 8–14 8–12
Mean duration of allergy (years) 4.7 3.11 4.1
Early skin response (mean area in mm2 at baseline7SD) 286.54772.66 297.58799.21 355.977100.5
Late skin response (mean area in mm2 at baseline7SD) 2003.937709.82 1926.157817.94 2611.717261.77
SLIT, sublingual immunotherapy.
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active treatment was standardized by a RAST-inhibition
procedure in comparison with a biologically standardized in-
house reference [13] and the content of the major allergen Par
j 1 was expressed in micrograms [14]. The extract was
prepared in ﬁve increasing concentrations (0.016, 0.08, 0.4, 2,
and 10BU/mL) in glycerinated and phenolated aqueous
solution. The top concentration (10BU/mL) contained
0.6mg/mL of the major allergen Par j 1. The administration
schedule was started with one drop of the most diluted vial,
and the amount was increased daily by one drop up to ﬁve
drops. The same procedure was repeated with each of the
following vials, so as to reach after 25 days the amount of ﬁve
drops from the most concentrated vial. The maintenance dose
of ﬁve drops of the strength 10BU/mL was thereafter
administered every other day until the end of October 2000
without changes during the pollen season. Drops had to be
taken in the morning at least 15min before eating and kept
under the tongue for at least 2min before swallowing. The
placebo was indistinguishable from the active treatment for
appearance, colour, and taste.
The cumulative amount of Par j 1 administered was around
20.3mg, i.e. around four times the dose normally administered
by the subcutaneous route for the same allergen in 13 months.
Apart from ﬂuticasone, to be administered twice daily from
April to June 2000 to all patients treated with SLIT (placebo
or active), anti-allergic drugs in the form of nedocromil
sodium eye drops and nasal spray were allowed on need,
along with the anti-histamine loratadine and the inhaled
b-agonist salbutamol. Nasal corticosteroids were not allowed.
Patients were asked to use allowed drugs regularly to
control symptoms.
If symptoms developed that were uncontrolled by regular
drugs, the co-ordinator could prescribe a 5-day course of
prednisone (1mg/kg/day).
Assessments
Symptom and drug scores All patients (or their parents)
were instructed to record daily symptom scores from April
to June on a diary card. The severity of individual symp-
toms was assessed on a 0–3 scale for chest (breath-
lessness, coughing, wheezing, and tightness), nose (sneezing,
blocking, and running), eyes (itching, redness, streaming, and
swelling).
Each drug administration was scored as follows: 1 point to
drugs for local administration (eye drop, nasal spray, or
inhaled salbutamol) and 2 points to drugs for systemic
administration (loratadine, syrup or tablet, or prednisone
tablet). The median weekly sum of symptom score and drug
intake score was calculated for analysis.
Visual analogue score (VAS) During the pollen season each
patient (or parent) was asked to indicate at 1-week intervals
his/her overall chest symptoms on a VAS (scale 0–10; 05 very
well, no symptoms; 105 very bad, heavy symptoms) answer-
ing the question: ‘How has your asthma been during the last 2
weeks?’
Early and late skin response Intradermal skin tests were
performed in all patients before starting the treatment in
September 1999 and again in October 2000 on the volar side
of the forearm with a biologically standardized aqueous
extract of P. judaica (Aquagen SQ-U, ALK-Abello´, Hor-
sholm, Denmark).
The size of the immediate (15min) and late phase (5 and
24h) cutaneous responses to the allergen (0.02mL of a 10
s.q.-U/mL solution) or control solution (0.02mL of saline
diluent) was assessed. The reaction size was calculated in mm2
taking into account the mean between the major diameter and
the perpendicular diameter at its mid-point.
Pollen counts The counts of Parietaria pollen grains in the
air of Messina for the observation period, expressed as weekly
mean of pollen grains/cubic meter of air, were obtained from
the local aerobiological service. The Burkard pollen trap
(VPPS 2000, Lanzoni, Bologna, Italy) was located on the roof
of a 15-m-high building inside the hospital.
Statistical analysis The analysis of non-parametric data was
performed by means of the Mann–Whitney U-test for
intergroup comparisons. Parametric data for intergroup
comparisons for early and late skin reactivity were analysed
by means of Student’s t-test and the variance test. The
t-paired test was used to analyse the change in the early and
late skin reactivity in each child before and after treatment.
P values o0.05 were considered as statistically signiﬁcant.
All statistical evaluations were performed with a standard
statistical software (BMDP Inc., Los Angeles, CA, USA).
Results
Balancing of groups
The three experimental groups were well balanced for age,
gender, and early and late skin response before treatment, as
shown in Table 1.
Compliance and tolerance to the treatment
The allergen up-dosing was performed in a hospital under the
supervision of a physician and with the availability of
resuscitation equipment. Maintenance dose was taken at
home and each patient (and parents) was regularly checked
every month with reference to the correct administration of
the treatment.
Thirty-four out of 38 children (89%) completed the study.
The four patients who dropped out were two from the
placebo–ﬂuticasone (P1F) group, one from the SLIT–
ﬂuticasone (S1F) group and one from the control group.
In both cases belonging to the P1F group, the drop out was
due to family problems. The drop out from the S1F group
was due to systemic reactions (abdominal pain, shortness of
breath, and wheezing) 20min after drops ingestion during the
maintenance phase. The patient from the control group
dropped out because of the appearance of another chronic
disease not related to asthma and/or allergy. These with-
drawals were therefore unlikely to have biased the statistical
results.
All patients who carried out the study completed diary
cards and the VASs.
The planned maintenance dose (ﬁve drops from the top
vial) was reached without any problem by all patients
belonging to the P1F Group and in all but one child
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belonging to the S1F group before the pollen season. In one
patient of the latter group, the maintenance dose was
decreased to three drops from vial 4 because of local
reactions (itching in the mouth and throat) just 1 week after
the peak pollen season (2 June). Tiredness after ingestion of
drops was reported by three patients belonging to the S1F
group and by two patients belonging to the P1F group. In all
cases, no adjustment of the dose was judged as necessary and
all ﬁve patients completed the study with no further
problems.
Clinical efficacy
Before the pollen season all patients were almost symptom
free and did not take any drugs. The onset of symptoms and
the need for treatment paralleled the pollen count, which is
shown in Fig. 1.
Total symptom scores and chest symptoms peaked on 26
May for the control group and on May 29 for S1F and P1F
groups, in good agreement with the average peak pollen
count (2 June). Owing to the different day being taken as
reference for the calculation of the weekly average value for
the pollen counts (Fig. 1), for chest symptoms scores (Fig.
2a), for drug scores (Fig. 3a), and for the VAS (Fig. 4a), there
was a slight apparent discrepancy between the peak of the
pollen season and the top scores.
Considering the overall season, chest symptoms, nose
symptoms, drugs scores, and the VASs were signiﬁcantly
better in both S1F and P1F compared with the control
group (P ranging from o0.001 and 0.043). For eye
symptoms, only the S1F group was signiﬁcantly better than
the control group (P5 0.025). A signiﬁcant difference could
be shown in favour of the S1F group as compared to the
P1F group for the VAS (P5 0.037) but not for chest
symptoms, drug scores, eye symptoms, and nose symptoms.
These results are summarized in Table 2. The behaviour of
chest symptoms, drug intake, and VAS is shown in detail in
Figs 2–4 (a and b). The difference between the control group
and the others two groups began to be signiﬁcant since the
ﬁfth week of the pollen season (for chest symptoms since
fourth week).
In no child belonging to the S1F group or to the P1F
group was there need for oral prednisone, whereas in four
patients of the control group, a total of ﬁve courses with this
drug were needed.
Early and late skin response
Table 3 summarizes the results of the skin tests in the three
groups. Before treatment there was no difference either for
the early (P5 0.242) or for the late skin response (P5 0.104)
among groups.
The early skin response decreased signiﬁcantly after
treatment in the S1F group ( 12.7%, Po0.001), whereas
the decrease was not signiﬁcant in both the P1F group
( 6.8%; P5 0.055) and the control group ( 0.6%;
P5 0.653). The change in the S1F group was statistically
signiﬁcant in comparison to the control group (P5 0.007),
whereas other comparisons did not reach the statistical
signiﬁcance.
The late skin response changed signiﬁcantly in all groups,
but it showed a different evolution in the S1F group as
compared to the P1F group and the control group. This
parameter decreased by 70.65% (Po0.0001, comparison
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Fig. 1. Parietaria average weekly pollen counts (grains/m3) in the air of
Messina (Sicily), April–June 2000.
Fig. 2. (a) Medians (7SEM) of the weekly sum of chest symptoms during
the 2000 Parietaria pollen season in the three experimental groups, with the
significant differences marked as asterisks. (b) Comparison of the overall
chest symptom score (median795% CI) for the whole season, with the
intergroup P-values.
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before–after treatment) in the active S1F group, whereas an
increase by 10.15% in the P1F group (P5 0.019) and by
11.25% in the control group (P5 0.037) took place.
The change in the S1F group was statistically signiﬁcant in
comparison with both the P1F group and the control group
(Po0.0001).
Discussion
Many well-tolerated drugs are currently available to control
allergy symptoms. On the other hand, many papers have
shown that SLIT is clinically effective in comparison with
placebo [1, 2]. Drugs are expected to act promptly after
administration, whereas speciﬁc immunotherapy is expected
to exert a slower efﬁcacy, followed by a long lasting
preventive effect – not yet shown for drugs – on further
sensitizations [15–17] and development of asthma [18].
The key issue that troubles most physicians treating
asthmatic children and adults is how immunotherapy
compares with pharmacotherapy. The pharmacological
treatment is an effective and quite safe therapy but it acts
in a non-speciﬁc manner on allergic inﬂammation and its
symptoms, whereas immunotherapy is an allergen-oriented
treatment able to affect both immunological and inﬂamma-
tory response thus modifying – especially in children – the
clinical history of the allergic respiratory disease. It is
therefore tempting to conclude that drugs and allergen
immunotherapy are not alternative treatments but comple-
mentary strategies.
This trial was therefore planned to assess if speciﬁc
immunotherapy through the sublingual route combined with
the administration twice daily of ﬂuticasone propionate may
be helpful in children suffering from seasonal asthma and
rhinoconjunctivitis due to P. judaica pollen, who experienced
a poor symptom control in previous years despite an optimal
pharmacological anti-allergic treatment including antihista-
mines, inhaled corticosteroids, and nedocromil sodium.
Fig. 3. (a) Medians (7SEM) of the weekly sum of drug intake scores
during the 2000 Parietaria pollen season in the three experimental groups,
with the significant differences marked as asterisks. (b) Comparison of the
overall scores (median795% CI) for the whole season, with the intergroup
P-values.
Fig. 4. (a) Median (7SEM) of the weekly sum of visual analog scores
during the 2000 Parietaria pollen season in the three experimental groups,
with the significant differences marked as asterisks. (b) Comparison of the
overall scores (median795% CI) for the whole season, with the intergroup
P-values.
Table 2. Clinical scores calculated for the whole pollen season: intergroup
comparisons
Parameter S1F vs. P1F S1F vs. control P1F vs. control
Non-parametric data – P-values for intergroup comparisons
Visual analog score 2000 0.037* o0.001** o0.001**
Chest symptoms 0.191 o0.001** o0.001**
Drug score 0.192 o0.001** 0.002**
Eye symptoms 0.340 0.025* 0.134
Nose symptoms 0.059 o0.001** 0.043*
S1F, sublingual immunotherapy plus fluticasone; P1F, placebo plus
fluticasone. *Statistically significant difference; **statistically high significant
difference.
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Our data show that the addition of ﬂuticasone propionate
(combined or not to active SLIT) to the standard sympto-
matic anti-allergic treatment is clinically effective, as already
documented by other papers [19, 20], because a statistically
signiﬁcant improvement as compared to the control group
was seen for chest symptoms, nose symptoms, and drug
scores. However, the combination of SLIT and ﬂuticasone led
to a statistically signiﬁcant improvement as compared to the
control group for eye symptoms, early skin response, and late
skin response. Moreover, the use of active S1F as compared
to placebo S1F led to a signiﬁcant improvement in the VAS
and in the late skin response.
The administration of SLIT in children is therefore able to
further increase the clinical beneﬁts, as judged from subjective
parameters, obtainable from the standard symptomatic
pharmacological treatment plus ﬂuticasone twice a day
already during the ﬁrst pollen season after the beginning of
the administration. The SLIT administration for 12 months
was also able, in our trial, to decrease signiﬁcantly two
objective parameters such as the early and late skin response
to the allergen. These results were obtained with a good
tolerance of the treatment and using allergen dosages already
documented as effective and safe in adults [7–10]. Moreover,
our patients had been selected among those who had shown
in the previous years a poor beneﬁt after treatment with
standard anti-allergic symptomatic drugs. It is interesting to
underline that the early and the late skin response showed an
opposite trend, because they increased signiﬁcantly in both
the control group and the placebo S1F group whereas they
signiﬁcantly decreased in the active S1F group. A decrease in
the early skin reactivity after speciﬁc immunotherapy has
already been documented for both injective and SLIT therapy
through the skin prick test [21–24]. A decrease in the late skin
response has been already documented for the injective
immunotherapy [25–27], and also in one trial where very high
dosages of grass allergens (about 40 times the cumulative dose
administered by the subcutaneous route) were administered
through the sublingual route in adults [28]. In spite of the high
dosage and of the signiﬁcant change in this objective
parameter, this study led to inconclusive results about the
clinical efﬁcacy of the treatment. In our trial, run in children,
we have been able to show that a signiﬁcant change in both
the early and the late skin response to the allergen can be
obtained with a cumulative allergen dosage only 4-fold higher
than the dose administered for the same allergen through the
subcutaneous route.
In conclusion, the clinical efﬁcacy of S1F is equal to that of
ﬂuticasone alone, but the addition of SLIT has also effects on
non-bronchial symptoms in patients under an optimal
pharmacological treatment.
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